Itolizumab is under clinical development by Equillium and currently in Phase I for Systemic Lupus Erythematosus. According to GlobalData, Phase I drugs for Systemic Lupus Erythematosus have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Itolizumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Itolizumab overview
Itolizumab (T1h, Alzumab / Anti-CD6 ) is a humanized recombinant anti-CD6 monoclonal antibody. It is formulated as injection solution for intravenous infusion. It is indicated for the treatment of patients with active moderate to severe chronic plaque psoriasis who are candidates for systemic therapy. Alzumab is indicated for emergency use in the treatment of cytokine release syndrome (CRS) in moderate to severe ARDS (acute respiratory distress syndrome) patients due to COVID-19.
Itolizumab is under development for the treatment of systemic lupus erythematosus, acute graft-versus-host disease (aGVHD), lupus nephritis, ulcerative colitis and chronic graft-versus-host disease (cGVHD). It is administered through intravenous and subcutaneous route.
It was also under development for the treatment of Coronavirus disease 2019 (COVID-19), vitiligo, psoriatic arthritis, psoriasis, rheumatoid arthritis, multiple sclerosis, dermatological disorders, refractory lupus nephritis and severe asthma.
Equillium overview
Equillium is a clinical-stage biotechnology company. It focuses on the development of novel therapeutics for severe autoimmune and inflammatory disorders. The company’s products include EQ101, a selective tri-specific cytokine inhibitor, EQ302, an orally delivered, selective bi-specific cytokine inhibitor, and Itolizumab, a monoclonal antibody to treat a variety of inflammatory conditions and diseases such as alopecia areata, lupus/lupus nephritis, and acute graft-versus-host disease (aGVHD). Its products are primarily used in the healthcare industry, specifically in the treatment of patients with severe autoimmune and inflammatory disorders. The company operates in Australia, the US and New Zealand. Equillium is headquartered in La Jolla, California, the US.
For a complete picture of Itolizumab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
